Global Gemtuzumab Ozogamicin Drugs Market

Gemtuzumab Ozogamicin Drugs Comprehensive Study by Type (5mg/Vial, 4.5mg/Vial), Application (Hospital, Pharmacy) Players and Region - Global Market Outlook to 2030

Gemtuzumab Ozogamicin Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 13.98%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Gemtuzumab Ozogamicin Drugs Market Overview:
Gemtuzumab Ozogamicin (GO) is the first Antibody-Drug Conjugate (ADC) approved for acute myeloid leukaemia (AML) induction therapy. When paired with standard cytarabine/anthracycline-based induction chemotherapy in fractionated doses, GO substantially increases the outcome in previously untreated AML patients.. The US Food and Drug Administration (FDA) approved Gemtuzumab Ozogamicin (GO) in 2000 for the treatment of newly diagnosed CD33+ Acute Myeloid Leukaemia in adults and CD33+ Acute Myeloid Leukaemia in children aged 2 years who have had a relapse or who have not responded to initial treatment. As per latest study released by AMA Research, the Global Gemtuzumab Ozogamicin Drugs market is expected to see growth rate of 13.98%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Growing Investments in Healthcare Infrastructure

Market Growth Drivers:
Prevalence of Acute Myeloid Leukemia (AML) and Growing Geriatric Population

Challenges:
Side Effects and Adverse Reactions and Regulatory Approval

Restraints:
Lack of Trained Professionals

Opportunities:
Low Penetration in Emerging Economies Particularly in Asian Region and Emergence of Advance and Effective Techniques

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Pfizer (United States), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi S.A. (France), Merck & Co., Inc. (United States), Novartis International AG (Switzerland), Bristol-Myers Squibb Company (United States), Johnson & Johnson Services, Inc. (United States), GlaxoSmithKline plc (United Kingdom), Eli Lilly and Company (United States) and Amgen Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like AbbVie Inc. (United States), AstraZeneca plc (United Kingdom), Celgene Corporation (United States), Takeda Pharmaceutical Company Limited (Japan) and Teva Pharmaceutical Industries Ltd. (Israel). Analyst at AMA Research see Global Players to retain maximum share of Global Gemtuzumab Ozogamicin Drugs market by 2030.

Latest Market Insights:
In December 2023, the US Food and Drug Administration (FDA) approved a new formulation of GO, marketed as Trodelvy, for the treatment of adult patients with acute myeloid leukemia (AML) with specific genetic mutations. This is significant because it expands the potential patient population for this drug.

In July 2023, The European Medicines Agency (EMA) approves Mylotarg® for the same expanded use case in adults with newly diagnosed FLT3-mutated AML

United States, Code of Federal Regulations 21, “MYLOTARG (gemtuzumab ozogamicin) for injection” - USDA is the key Regulatory Authority Responsible for Approval, Inspection and Dosage Limitations of MYLOTARG across the United States, FDA limits the usage to licensed prescription holders only. Any New Entrant is Required to have a Regulatory Clearance form FDA.

What Can be Explored with the Gemtuzumab Ozogamicin Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Gemtuzumab Ozogamicin Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Gemtuzumab Ozogamicin Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Gemtuzumab Ozogamicin Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Gemtuzumab Ozogamicin Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants and Investors, Gemtuzumab Ozogamicin Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • 5mg/Vial
  • 4.5mg/Vial
By Application
  • Hospital
  • Pharmacy
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Acute Myeloid Leukemia (AML)
      • 3.2.2. Growing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Side Effects and Adverse Reactions
      • 3.3.2. Regulatory Approval
    • 3.4. Market Trends
      • 3.4.1. Growing Investments in Healthcare Infrastructure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gemtuzumab Ozogamicin Drugs, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gemtuzumab Ozogamicin Drugs (Value)
      • 5.2.1. Global Gemtuzumab Ozogamicin Drugs by: Type (Value)
        • 5.2.1.1. 5mg/Vial
        • 5.2.1.2. 4.5mg/Vial
      • 5.2.2. Global Gemtuzumab Ozogamicin Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Pharmacy
      • 5.2.3. Global Gemtuzumab Ozogamicin Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Gemtuzumab Ozogamicin Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi S.A. (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis International AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson Services, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gemtuzumab Ozogamicin Drugs Sale, by Type, Application and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gemtuzumab Ozogamicin Drugs (Value)
      • 7.2.1. Global Gemtuzumab Ozogamicin Drugs by: Type (Value)
        • 7.2.1.1. 5mg/Vial
        • 7.2.1.2. 4.5mg/Vial
      • 7.2.2. Global Gemtuzumab Ozogamicin Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Pharmacy
      • 7.2.3. Global Gemtuzumab Ozogamicin Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gemtuzumab Ozogamicin Drugs: by Type(USD Million)
  • Table 2. Gemtuzumab Ozogamicin Drugs 5mg/Vial , by Region USD Million (2018-2023)
  • Table 3. Gemtuzumab Ozogamicin Drugs 4.5mg/Vial , by Region USD Million (2018-2023)
  • Table 4. Gemtuzumab Ozogamicin Drugs: by Application(USD Million)
  • Table 5. Gemtuzumab Ozogamicin Drugs Hospital , by Region USD Million (2018-2023)
  • Table 6. Gemtuzumab Ozogamicin Drugs Pharmacy , by Region USD Million (2018-2023)
  • Table 7. South America Gemtuzumab Ozogamicin Drugs, by Country USD Million (2018-2023)
  • Table 8. South America Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 9. South America Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 10. Brazil Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 11. Brazil Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 12. Argentina Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 13. Argentina Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 14. Rest of South America Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 15. Rest of South America Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 16. Asia Pacific Gemtuzumab Ozogamicin Drugs, by Country USD Million (2018-2023)
  • Table 17. Asia Pacific Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 18. Asia Pacific Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 19. China Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 20. China Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 21. Japan Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 22. Japan Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 23. India Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 24. India Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 25. South Korea Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 26. South Korea Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 27. Taiwan Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 28. Taiwan Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 29. Australia Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 30. Australia Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 31. Rest of Asia-Pacific Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 32. Rest of Asia-Pacific Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 33. Europe Gemtuzumab Ozogamicin Drugs, by Country USD Million (2018-2023)
  • Table 34. Europe Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 35. Europe Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 36. Germany Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 37. Germany Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 38. France Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 39. France Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 40. Italy Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 41. Italy Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 42. United Kingdom Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 43. United Kingdom Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 44. Netherlands Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 45. Netherlands Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 46. Rest of Europe Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 47. Rest of Europe Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 48. MEA Gemtuzumab Ozogamicin Drugs, by Country USD Million (2018-2023)
  • Table 49. MEA Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 50. MEA Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 51. Middle East Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 52. Middle East Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 53. Africa Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 54. Africa Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 55. North America Gemtuzumab Ozogamicin Drugs, by Country USD Million (2018-2023)
  • Table 56. North America Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 57. North America Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 58. United States Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 59. United States Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 60. Canada Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 61. Canada Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 62. Mexico Gemtuzumab Ozogamicin Drugs, by Type USD Million (2018-2023)
  • Table 63. Mexico Gemtuzumab Ozogamicin Drugs, by Application USD Million (2018-2023)
  • Table 64. Company Basic Information, Sales Area and Its Competitors
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Gemtuzumab Ozogamicin Drugs: by Type(USD Million)
  • Table 75. Gemtuzumab Ozogamicin Drugs 5mg/Vial , by Region USD Million (2025-2030)
  • Table 76. Gemtuzumab Ozogamicin Drugs 4.5mg/Vial , by Region USD Million (2025-2030)
  • Table 77. Gemtuzumab Ozogamicin Drugs: by Application(USD Million)
  • Table 78. Gemtuzumab Ozogamicin Drugs Hospital , by Region USD Million (2025-2030)
  • Table 79. Gemtuzumab Ozogamicin Drugs Pharmacy , by Region USD Million (2025-2030)
  • Table 80. South America Gemtuzumab Ozogamicin Drugs, by Country USD Million (2025-2030)
  • Table 81. South America Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 82. South America Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 83. Brazil Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 84. Brazil Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 85. Argentina Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 86. Argentina Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 87. Rest of South America Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 88. Rest of South America Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 89. Asia Pacific Gemtuzumab Ozogamicin Drugs, by Country USD Million (2025-2030)
  • Table 90. Asia Pacific Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 91. Asia Pacific Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 92. China Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 93. China Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 94. Japan Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 95. Japan Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 96. India Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 97. India Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 98. South Korea Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 99. South Korea Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 100. Taiwan Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 101. Taiwan Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 102. Australia Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 103. Australia Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 104. Rest of Asia-Pacific Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 105. Rest of Asia-Pacific Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 106. Europe Gemtuzumab Ozogamicin Drugs, by Country USD Million (2025-2030)
  • Table 107. Europe Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 108. Europe Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 109. Germany Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 110. Germany Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 111. France Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 112. France Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 113. Italy Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 114. Italy Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 115. United Kingdom Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 116. United Kingdom Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 117. Netherlands Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 118. Netherlands Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 119. Rest of Europe Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 120. Rest of Europe Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 121. MEA Gemtuzumab Ozogamicin Drugs, by Country USD Million (2025-2030)
  • Table 122. MEA Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 123. MEA Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 124. Middle East Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 125. Middle East Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 126. Africa Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 127. Africa Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 128. North America Gemtuzumab Ozogamicin Drugs, by Country USD Million (2025-2030)
  • Table 129. North America Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 130. North America Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 131. United States Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 132. United States Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 133. Canada Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 134. Canada Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 135. Mexico Gemtuzumab Ozogamicin Drugs, by Type USD Million (2025-2030)
  • Table 136. Mexico Gemtuzumab Ozogamicin Drugs, by Application USD Million (2025-2030)
  • Table 137. Research Programs/Design for This Report
  • Table 138. Key Data Information from Secondary Sources
  • Table 139. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gemtuzumab Ozogamicin Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Gemtuzumab Ozogamicin Drugs: by Application USD Million (2018-2023)
  • Figure 6. South America Gemtuzumab Ozogamicin Drugs Share (%), by Country
  • Figure 7. Asia Pacific Gemtuzumab Ozogamicin Drugs Share (%), by Country
  • Figure 8. Europe Gemtuzumab Ozogamicin Drugs Share (%), by Country
  • Figure 9. MEA Gemtuzumab Ozogamicin Drugs Share (%), by Country
  • Figure 10. North America Gemtuzumab Ozogamicin Drugs Share (%), by Country
  • Figure 11. Global Gemtuzumab Ozogamicin Drugs share by Players 2023 (%)
  • Figure 12. Global Gemtuzumab Ozogamicin Drugs share by Players (Top 3) 2023(%)
  • Figure 13. Global Gemtuzumab Ozogamicin Drugs share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 16. Pfizer (United States) Revenue: by Geography 2023
  • Figure 17. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 19. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 21. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 25. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 27. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 33. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Global Gemtuzumab Ozogamicin Drugs: by Type USD Million (2025-2030)
  • Figure 36. Global Gemtuzumab Ozogamicin Drugs: by Application USD Million (2025-2030)
  • Figure 37. South America Gemtuzumab Ozogamicin Drugs Share (%), by Country
  • Figure 38. Asia Pacific Gemtuzumab Ozogamicin Drugs Share (%), by Country
  • Figure 39. Europe Gemtuzumab Ozogamicin Drugs Share (%), by Country
  • Figure 40. MEA Gemtuzumab Ozogamicin Drugs Share (%), by Country
  • Figure 41. North America Gemtuzumab Ozogamicin Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Sanofi S.A. (France)
  • Merck & Co., Inc. (United States)
  • Novartis International AG (Switzerland)
  • Bristol-Myers Squibb Company (United States)
  • Johnson & Johnson Services, Inc. (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Eli Lilly and Company (United States)
  • Amgen Inc. (United States)
Additional players considered in the study are as follows:
AbbVie Inc. (United States) , AstraZeneca plc (United Kingdom) , Celgene Corporation (United States) , Takeda Pharmaceutical Company Limited (Japan) , Teva Pharmaceutical Industries Ltd. (Israel)
Select User Access Type

Key Highlights of Report


Mar 2024 233 Pages 88 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gemtuzumab Ozogamicin Drugs Market Quantitative research analysis
Global Gemtuzumab Ozogamicin Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Gemtuzumab Ozogamicin Drugs market are Pfizer (United States), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi S.A. (France), Merck & Co., Inc. (United States), Novartis International AG (Switzerland), Bristol-Myers Squibb Company (United States), Johnson & Johnson Services, Inc. (United States), GlaxoSmithKline plc (United Kingdom), Eli Lilly and Company (United States) and Amgen Inc. (United States), to name a few.
"Growing Investments in Healthcare Infrastructure" is seen as one of major influencing trends for Gemtuzumab Ozogamicin Drugs Market during projected period 2023-2030.
5mg/Vial segment in Global market to hold robust market share owing to "Prevalence of Acute Myeloid Leukemia (AML) ".

Know More About Global Gemtuzumab Ozogamicin Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Terbinafine Tablet Comprehensive Study by Application (Athlete's Foot, Jock Itch, Ringworm, Others), Route of Administration (Oral Medication, External Medicine), Distribution Channel (Hospital Pharm...
$ 3450
Psychotherapeutics Drugs Comprehensive Study by Application (Schizophrenia, Dementia, Bipolar, Unipolar Depression), Drugs Class (Antipsychotic Drugs, (Thioxanthenes, Atypical Antipsychotics, Phenoth...
$ 3750
Timolol Comprehensive Study by Type (Tablet (5mg, 10mg and 20mg), Eye Drops (3ml Drops, 5ml Drops and Others)), Application (Open-Angle Glaucoma, Ocular Hypertension), Distribution Channel (Hospital ...
$ 3450
Glycine Supplement Comprehensive Study by Application (Sleep Problems, Joint and Bone Health, Cardiovascular Diseases, Others), Distribution Channel (Retail Store, Online Store, Others), Dosage Form ...
$ 3500
Ketotifen Fumarate Comprehensive Study by Application (Asthma, Allergic rhinitis, Allergic conjunctivitis, Atopic dermatitis, Chronic urticarial, Cold -induced urticarial, Cholinergic urticarial,...
$ 3750
Tygacil Comprehensive Study by Type (Gram-Positive Bacteria, Gram-Negative Bacteria), Application (Urinary Tract Infections (UTI), Skin and Soft Tissue Infections, Complicated Intra-Abdominal Infecti...
$ 3750